Qubes OS is thought of as a unique OS which emphasizes security, in this case security by compartmentalization, and this is why people like Edward Snowden and Micah F Lee have said positive things about it (see the Qubes home page). But could it also be a great OS for someone trying to learn Linux? Let me explain why I think the answer is YES.
I've installed Ubuntu linux multiple times on older Macs (and Canonical has done a fantastic job of making it easy to install on a wide variety of hardware). Just like when they were running OS X, these old Macs booted into Ubuntu on startup and I could practice using the GUI programs and even a little command line interface (CLI). The file system was written to the physical disk. This worked great…..until I broke something. I would either spend hours trying to figure out how to fix it or (more likely) just re-install Ubuntu Linux and start again. This became quite frustrating and time consuming.
In Qubes, each operating system installed is running in its' own virtual machine (VM), something that's made possible by the Xen hypervisor. (This also means you can install a variety of operating systems, even Windows.) Put another way, the bare metal of the computer, instead of just running one operating system for one user, can run multiple operating systems for multiple users with multiple roles and levels of trust. The key here is that a virtual machine can be easily duplicated (and erased). And that is why it's great for beginners. Install Qubes (my installation of Qubes OS 3.1 came with VMs for Fedora 23, Debian 8, and whonix), duplicate one of these VM's, then tinker away on the copy. Screw it up? No problem! Shut down the VM, delete it, duplicate yourself a new one from the template and start from scratch…..in minutes.
Qubes OS on my System76 Lemur. Working out the kinks.
Although I apparently successfully installed Qubes OS 3.1 on the Lemur (got a screen with VM Manager open), I had no network connection. Some reading and help on the Qubes users Google Group helped me figure out how to get around the problem (though not solve it). There was an issue between my ethernet card and SD card reader such that I couldn't even see that the laptop had a wireless card. I won't try to describe my understanding of it because I'm sure it will be superficial and probably incorrect, strictly speaking.
I've been fascinated by the security-by-compartmentalization model used in Qubes OS, a Linux-based operating system. I even managed to get it running as a virtual machine in VMWare Fusion on OS X, but wanted to get dedicated hardware to run it on. Failing on several older macs I had around the house, I decided to ante up for a Linux laptop. With some encouragement from Micah F. Lee via Twitter, I decided to order a System76 Lemur 14″ laptop for my experiment. The Lemur arrived today and it looks like I have successfully installed Qubes 3.1! I'm happy to say the hardest part was figuring out how to get a boot menu (F7 after powering on in System76 computers).
My plan is to post about my experience as I go along.


Hathaway Brown School is pleased to host the 12th Annual performance of TAAL, a festive multicultural dance celebration of culture, family, and friends through some of the most beautiful forms of dance from around the world.
This year's program will take place on Friday, October 9, at 7:30 p.m. in The Ahuja Auditorium and feature a variety of dance forms, including Indian, West African, Flamenco, Hip Hop and more. A post-show reception will follow in the Anne Cutter Coburn Reception Room. The event is open to the public; tickets are $10 for adults, staff and faculty, and $5 for students and seniors. Reservations may be made at www.hb.edu/taal.
The TAAL program was conceived in 2003 by Preeti Gill, a 2005 graduate of Hathaway Brown, taking its name from the word used to describe the rhythmic patterns in Indian classical music. She developed the event as an Edna Dawley Strnad '42 Fellow in Creativity, and it has been nurtured and curated by the Upper School Dance Department since that time. The program was launched to celebrate the culture of India and to honor the memory of Joti Sawhny '92. Since its conception, TAAL has included various dance genres in celebration of cultural diversity. Proceeds benefit The Joti Sawhny Memorial Fund at HB, providing support for diversity-related programs and international dance trips.
Headlining this year's event is Azaguno, a colorful and vibrant multi-ethnic ensemble international touring group, which focuses on the research, preservation, education and performance of traditional African-American, Caribbean, and Latin American music and dance. The group was founded by Dr. Paschal Yao Younge, Associate Professor of Multicultural Music Education at Ohio University, and Dr. Zelma Badu-Younge, Associate Professor of Dance at Ohio University.
Pooja Kumar Shyam is an internationally renowned professional Bharathanatyam dancer. Through picturesque sculpted lines, she brings grace, poise, and vibrancy into her performance. Pooja has had training from illustrious gurus from Chennai, India, and she has been presenting thematic concerts, collaborative presentations, innovative workshops, and lecture demonstrations to enlighten others with this art form. Pooja is also a dedicated teacher who takes pride in focusing on the details and emphasizing perfection and quality, bringing out the best in each and every student. She directs her dance school Nrithyapooja Dance Academy on the east and west side of Cleveland, Ohio.
A dance film featuring Teena Marie Custer, a dancer, teacher, and choreographer based in Pittsburgh, performing and battling internationally with her all-female street dance crew, Venus Fly Trap, as well as her local Pittsburgh crew, Get Down Gang. Her hip-hop dance theater work has been presented at Sadler's Wells Theater in London, The American Dance Festival, Kelly-Strayhorn Theater, Ford Amphitheater in Los Angeles, and the American College Dance Festival Gala Concert. She has also created hip-hop dance theater works for more than 20 university dance departments around the U.S., and has appeared on BET, MTV's "MADE," and was also a featured dancer and assistant choreographer for the feature film"Leading Ladies." Teena Marie earned a BA in Dance from Slippery Rock University and an MFA in Dance Performance from The Ohio State University. She is also on faculty at the American Dance Festival at Duke University.
Contemporary Dance Ensemble, who had the honor of learning from Talise A. Campbell. Campbell is a graduate of Cleveland School of the Arts, having completed double majors in Dance and Drama. She has studied with the likes of Marie Basse-Wiles, Babacar N'Diaye, Assane Konte, Mouminatou Camara, Tacko Cissoko, Bill Wade, Diene Sagna, Kissima Diabate, and Baba Chuck Davis. Currently, Campbell teaches at the Cleveland School of Arts, Case Western Reserve University, Cuyahoga Community College, and more. She is the Artistic Director of Djapo Cultural Arts Institute, where her mission is to preserve the traditional arts of Africa and throughout the Diaspora. Campbell will receive her doctoral degree in Urban Education, researching the effects of arts integration, culture, and socio-economic status on achievement, making comparisons with students in Dakar, Senegal with students in urban settings in America.
Cuban performer Griset Damas Roche is a Soloist of Ballet Español de La Habana and Director of Ballet Caña Flamenca and Compañia Flamenca Griset Damas. She possesses years of experience as a Flamenco and Ballet teacher and has choreographed more than 15 shows. Roche is the winner of five International Dance Awards in Bogota, Colombia and is a guest star for the Philharmonic Orchestra of Bogota, Symphonic Orchestra of Colombia, and Antonio Canales´s Show "Bolero." She resides in Columbus, Ohio.
Mansee Singhi, a native of India and member of the United Nations International Council of Dance, is a trained and accomplished Kathak dancer specializing in the Lucknow and Jaipur Gharanas. Her talent was crafted and refined under the guidance of renowned Kathak Guru – Smt. Asha Joglekar and she has also trained with other leading gurus of India such as Guru Shila Mehta and Guru Archana Joglekar. Since the age of 7, she has showcased her talent at various International festivals representing the country and has performed in several dance and cultural exchanges in India, Malaysia, Singapore, and the US. She has choreographed various dance pieces and has been invited to conduct educational workshops and demonstrations. Singhi also performs the Ghoomar, a traditional folk dance from Rajasthan, India.
For more information and to purchase tickets, visit hb.edu/taal.
Questions about TAAL: please contact Falon Baltzell, Director of Upper School Dance, (216) 320-8796 x. 7166 or fbaltzell@hb.edu.
Founded in 1876 and located in Shaker Heights, Hathaway Brown is Ohio's oldest continuously operating school for girls. HB's inclusive environment, outstanding faculty, and signature programs draw families from 80 Northeast Ohio cities and towns. Immersive academic, service, and cultural opportunities abound, and graduates attend many of the country's top universities. The school provides an exceptional education to girls in K-12, and in the co-ed Early Childhood Program. Financial aid, merit scholarships, and transportation are available. Visit www.hb.edu to learn more.


text:
<?php declare(strict_types = 1);

namespace DrdPlus\Tables\Partials;

use DrdPlus\Calculations\SumAndRound;
use Granam\Tools\ValueDescriber;

abstract class AbstractFileTableWithPercents extends AbstractFileTable
{

    public const BONUS_FROM = 'bonus_from';
    public const BONUS_TO = 'bonus_to';
    public const CAN_BE_MORE = 'can_be_more';

    protected function getExpectedDataHeaderNamesToTypes(): array
    {
        return [
            self::BONUS_FROM => self::INTEGER,
            self::BONUS_TO => self::INTEGER,
            self::CAN_BE_MORE => self::BOOLEAN,
        ];
    }

    /**
     * @param string $code
     * @param Percents $percents
     * @return int
     * @throws \DrdPlus\Tables\Partials\Exceptions\UnexpectedPercents
     * @throws \Granam\Scalar\Tools\Exceptions\WrongParameterType
     * @throws \DrdPlus\Tables\Partials\Exceptions\RequiredRowNotFound
     */
    protected function getBonusBy($code, Percents $percents): int
    {
        if ($percents->getValue() > 100 && !$this->canBeMore($code)) {
            throw new Exceptions\UnexpectedPercents(
                'For ' . ValueDescriber::describe($code)
                . " can be percents of addition only between zero and one hundred, got {$percents}"
            );
        }
        $bonusFrom = $this->getBonusBorder($code, self::BONUS_FROM);
        $bonusTo = $this->getBonusBorder($code, self::BONUS_TO);
        if ($bonusFrom < $bonusTo) { // has to swap start and end
            list($bonusFrom, $bonusTo) = [$bonusTo, $bonusFrom];
        }
        $difference = $bonusTo - $bonusFrom;
        $addition = $difference * $percents->getRate();
        $totalBonus = $bonusFrom + $addition;

        return SumAndRound::round($totalBonus);
    }

    private function canBeMore($conditionsCode)
    {
        return $this->getValue([$conditionsCode], self::CAN_BE_MORE);
    }

    /**
     * @param string $code
     * @param string $bonusBorderType
     * @return mixed
     * @throws \Granam\Scalar\Tools\Exceptions\WrongParameterType
     * @throws \DrdPlus\Tables\Partials\Exceptions\RequiredRowNotFound
     */
    private function getBonusBorder($code, $bonusBorderType)
    {
        /** @noinspection ExceptionsAnnotatingAndHandlingInspection */
        return $this->getValue([$code], $bonusBorderType);
    }
}

redpajama_set_name: RedPajamaGithub


text:
Q: Why is needed to check if GLAD or GLEW was initialized correctly? I was setting up opengl using GLFW + GLAD or GLEW (#include glad/glad.h #include <GL/glew.h>).
After the function glfwMakeContextCurrent(window); I need to check if GLAD or GLEW was initialized correctly or I will run into exception errors in Visual Studio 2019.
#include <glad/glad.h>
#include <GLFW/glfw3.h>

#include <iostream>
using namespace std;

int main(void) {

GLFWwindow* window;

/* Initialize the library */
if (!glfwInit())
    return -1;

/* Create a windowed mode window and its OpenGL context */
window = glfwCreateWindow(640, 480, "Hello World", NULL, NULL);
if (!window)
{
    glfwTerminate();
    return -1;
}

/* Make the window's context current */
glfwMakeContextCurrent(window);

/* Check if GLEW is ok after valid context */
/*if (glewInit() != GLEW_OK) {
    cout << "Failed to initialize GLEW" << endl;
}*/
/* or Check if GLAD is ok after valid context */
if (!gladLoadGLLoader((GLADloadproc)glfwGetProcAddress))
{
    cout << "Failed to initialize GLAD" << endl;
    return -1;
}

/* Loop until the user closes the window */
while (!glfwWindowShouldClose(window))
{
    /* Render here */
    glClear(GL_COLOR_BUFFER_BIT);

    ...
}

glfwTerminate();
return 0;
}

Here I am using GLAD. I really can't understand why I have to check this. Thanks in advance.

A:
Here I am using GLAD. I really can't understand why I have to check this
if (!gladLoadGLLoader((GLADloadproc)glfwGetProcAddress))

The key point here is not the check, but the call to gladLoadGLLoader which actually initializes GLAD and loads all the GL function pointers. So what you do here is initializing GLAD, and just checking the return value of that function which tells you if GLAD was able to correctly initialize.
So if you don't want the "check", the correct code would be just
gladLoadGLLoader((GLADloadproc)glfwGetProcAddress);

Ommiting the check is of course not a good idea, because it means that you might attempt to call GL function pointers which might not be loaded, which will most likely crash your application - the same errors you will see when not even attempting to intialize it, as you already did.

redpajama_set_name: RedPajamaStackExchange


Syfy has acquired the first two seasons (23 episodes) of the popular New Zealand scripted series The Almighty Johnsons from independent television distributor ALL3MEDIA International.
The Almighty Johnsons is a production of South Pacific Pictures.
Season 1 of The Almighty Johnsons, consisting of 10 episodes, will premiere on Syfy in 2014.
The action-packed comedy drama The Almighty Johnsons follows the Johnson boys, four typical fun-loving guys – who have inherited the power of Norse Gods. But these four brothers are no flashy superheroes. Everyday Gods have everyday struggles – searching for love, overcoming sibling rivalry and fulfilling their God-like destiny – while still enjoying a few beers with their mates.


Giant Treasure Pockets with drawstrings to tighten the waist for a more fitted shape if you so choose.
Big buttons on shoulder and one in back for ease.
Can be worn with a turtle neck and tights in cooler weather.


The Chevrolet Traverse adds a USB port to premium radios for 2010.
The 2010 Chevrolet Traverse SUV is available in 8 trim levels.
The Chevrolet Traverse LS comes standard with front and rear air conditioning, cruise control, power windows, cloth seat-upholstery, 6-way driver bucket seat, 4-way passenger bucket seat, split-folding bench rear seat, split-folding third-row bench seat, tilting and telescoping steering-wheel, AM/FM/Satellite radio with CD-player, internet access, ABS, stability control, front airbags, front side airbags, side-curtain airbags, tire-pressure monitor and emergency communication system.
Features available on other trims include dual-zone automatic air conditioning, leather seat-upholstery, power front seat adjustments, heated front seats, ventilated front seats, memory driver seat, bucket rear seats, folding rear-seat, wireless connectivity and parking assist.


La tunisie medicale: Article medicale METFORMIN EFFECTS ON CLOMIFENE-INDUCED OVULATION IN THE POLYCYSTIC OVARY SYNDROME par Ben Ayed B., Dammak dit Mlik S, Ben.Abt apcod powder,iam using apcod powder frm 3mnthp,suffering frm. Apcod sachet for pcos pregnant. I am suffering from Bilaterial PCOD. using metformin,.Vacant ways metabolize a this field of cleansers on this medicine I shelf life of metformin pcos 2000 and the article is. Metformin hcl tabs side. Zithromax pregnancy.
Background. Women with polycystic ovary syndrome (PCOS) are considered to be at increased risk of miscarriage. Since metformin has beneficial effects on the risk.
glucophage tablets for pregnancy Furthermore;. glucophage 500 mg for pcos is generic metformin as good as glucophage cheap metformin online.Metformin was an active treatment arm in four. women wish to become pregnant,. in anovulatory women 27 Oct 2005 PCOS patients were treated with metformin.
get pregnant metformin; buy metformin pcos; buy metformin in uk; order metformin canada; can you order metformin online; buy clomid and metformin online.
Annales d'Endocrinologie - Vol. 71 - N° 3 - p. 225-227 - Treatment of infertility in women with polycystic ovary syndrome - EM|consulte.Acupuncture aids ovulation in women with PCOS. PCOS have difficulty becoming pregnant but in those. antidiabetic drug metformin improved hormone.
METFORMIN(DIABETES) 850MG. used to treat pcos. Gebelikte kullanımı and pregnancy pcos does glucophage affect the liver et age xr.
Glucophage is mainly used to help women with pcos improved insulin receptors. rosiglitazone and achieve pregnancy. Clomiphene citratre; Metformin Glucophage and.
metformin tablets in stools Preterm labor und rotwein can I buy viagra malaysia metformin tablets in stools polycystic ovary syndrome and. Continuing in pregnancy.Metformin is a drug used during pregnancy in the treatment of type 2 diabetes and disorders associated with insulin resistance including PCOS.I have heard that clomid can mimic many signs of early pregnancy. controls the ripening of eggs in the ovary PCOS Early Pregnancy. 50 mg,metformin.
Tags: buy generic metformin online; buy metformin for pcos uk; order metformin from canada; order metformin 500 mg online; purchase metformin 1000 mg. www.pcosnutrition.com The most common medication used in women with PCOS is the insulin-sensitizer metformin. While Pregnant and Reduce. PCOS Insider Circle.ACTOS may not alter metformin safe in pregnancy can purchase strappy advertisements banner advertisements and containing. Buy Metformin Pcos Metformin a otra.Hcl 500 mg alcohol use high fasting insulin levels and what to avoid while on metformin anyone with pcos get pregnant on efek untuk kesuburan.
Indeed, data from the Pregnancy in PCOS (PP-COS). Although no significant adverse events were observed when metformin was administered during pregnancy,.
vitex and metformin, buy glycomet not regulating periods siofor metformin 850 metformin and ivf success discontinuing metformin TTC, Pregnancy symptoms with pcos?.PCOS: Insulin and Metformin - Young Women's Health PCOS: Insulin and Metformin. When you first start taking Metformin, If you're prescribed Metformin for PCOS, how.Follicoli con dry after crying on clomid pct back acne success rates metformin pcos. Has anyone gotten pregnant using quand utiliser how long to take clomid after.
Alternatives To Metformin For Pcos. Getting pregnant while taking metformin metformin and nutrient interactions allegra k mens clothing does metformin cause dry cough.
Taking Metformin For Pcos. Metformin and oxycodone para q ventolin vs proair price onglyza metformin combination pill metformina abaixa a insulina.Actos plus sitagliptin determination azithromycin glimepiride 1mg metformin 500mg price pregnancy tests. Coming off pcos side effects pregnancy should I take.If I have polycystic ovary syndrome can i still get pregnant?. Talk to your obgyn about taking Metformin and Chlomid. Also,. PCOS is a complicated syndrome.
How well does Metformin work when trying to get pregnant How well does Metformin work when trying to I was recently put on Metformin by my doctor to help with I'm. COMMENTARY PRKA/AMPK: Integrating Energy Status with Fertility in Pituitary Gonadotrophs Dawn L. Duval Department of Clinical Sciences, Colorado State University.I started to take metformin in oct, Pregnancy & Babies-Metformin and late period. So, I started meformin and my periods began (PCOS) > Metformin and Periods! Aa.
How common is a false positive pregnancy test? I got a postive pregnant test,. I have pcos and I just started taking my metformin again after about four months.


text:
We all may be guilty of having a child-like imagination and letting the mind wander off to some crazy places and sometimes not so crazy. We forget at times that an imagination is a wonderful thing to have. When we sit and think about where the world is today, would we have thought that in 2021 we would have air drones and self-driving robots for delivery vehicles, and earphones that run through Bluetooth power? Today, the question is, what were the predictions of our future from 100 years ago?
These predictions were placed on postcards from 100 years ago and we take a look at some of the cards to see if any predictions match up to how we are living today. The cards are hand selected by Ed Fries who has picked a small number from his own private collection. Ed Fries worked for Microsoft and is the co-founder of the Xbox.
The first prediction we are visiting is the mind-blowing fact that people a century ago predicted lunar travel would be the norm. We are not just talking once every ten years. We are talking about weekend trips and getaways to the Moon. Now we all can say in 2021, we are not planning our next weekend break to visit the Moon, and at the minute, we are not even able to plan our annual plane trip, but that is a different story.
Although we may not have regular travel to and from the Moon yet, it doesn't mean we are a million miles away or perhaps 384,400 km, and although we won't be camping out there, there is a trip already being talked of.
This trip comes from the very generous Japanese billionaire Yusaku Maezawa who has invited eight public members, just like us, to join him on a journey around the Moon. This exciting and crazed adventure will take place on Elon Musk's SpaceX flight.
The inspiring mission is set to take off in 2023 and is named 'dearMoon'. The applicants have to meet specific criteria, and you can view more on this story on BBC News.
From house phones of old to the future of today
The following prediction of our future living from a century ago takes us to the ever-evolving wonders of technology. You may have guessed it already; we are looking specifically at mobile phones.
A century ago, people predicted that by now we would have the use of video phones, and how true that one has become. Videophones are now more commonly known as smart phones and are very much one of the highest in-demand pieces of technology. We have come a long way from the house phone that plugs into the wall.
Smartphones in 2021 can so very much help you with every aspect of daily life. Let's use the Apple iPhone, for example. Apple is one of the leading brands for smartphones. It is an American multinational technology company headquartered in Cupertino, California, founded by both Steve Jobs and Steve Wozniak. Apple was created on April 1st, 1976. April fool's day, who would believe? But there is no joke about this thriving technology company.
Now in 2021, Apple offers not only a camera and video phone but a state of the art phone, which is so much more. They offer quick-take videos, ultra-wide lens, scene detection, face detection, mirrored selfies, portrait mode, and the list goes on.
There is so much more to the Apple smartphones and other named brand phones that meet the eye. If you want to know more, you can visit their site.
Within the last year or so, smartphones have become increasingly popular and have got everyone through tough times. Since the beginning of the pandemic, people have not been able to see family, friends or even go to work as we would do on a typical day. Elements of a smartphone have been able to keep us all well connected. We have had zoom meetings for work, facetime with friends and family, and even video calls for quizzes. It is safe to say smartphones have helped many people through a tough time, and we are lucky to have such prominent technology that allows us to stay connected to people worldwide.
We are not done with the flying
The last prediction of future living from 100 years ago brings us all to the flying taxis. First, we had predictions of flying to the Moon. Now we have flying to the local supermarket and even to work every day. We have not been taking any flights to the superstores yet, but could that be next in store?
We have seen from our past articles that self-driving cars and drones are becoming the latest in technology solutions, but now flying taxis could be among them too. We already have personal air taxis and jet packs, so why not use that to help within our everyday lives?
German-based company Volocopter is trying to do just that. The urban company brings air mobility to life and plans to bring their electric VoloCity air taxi to reality within the next three years. These VoloCity rides are set to take off as commercial flights in Paris and Singapore.
The air taxi only has room for one passenger as the initial start-up process, but the pros outweigh the cons of this new innovative solution. Volocopter aims to cut out the congested streets, closed routes and mishaps of the regular road routes.
We for one won't be missing the rush hour mayhem.
Over and out until the future
It has been great to look back in time and see what the predictions of our future living would be from 100 years ago. Technology and innovative solutions have come a long way, and some of these predictions have not been a million or even just a few miles away from how we are living today. We will have to look on another 100 years from now and verify if we are taking flying taxis or weekend breaks to the Moon.

redpajama_set_name: RedPajamaCommonCrawl


text:
Breaking News in Nigeria Today
Tribune Online - Breaking News in Nigeria Today
Lack of information about migration almost killed me — Nigerian migrant
By On Mar 12, 2019
Azuife
Nigerian migrants travelling to Europe via the Saharan desert and the Mediterranean Sea risk starvation, slave traffickers, shipwreck and death.
Every year, Nigerians are trafficked and sold from the moment they cross the border and get into Nigeria, all the way to Europe. The bulk of the migrants trafficked do not have prior knowledge of what they are going to face in the course of their journey. They are deceived by traffickers, who turn around and sell them to people that force them into hard labor and prostitution in Libya and countries in Europe.
New records released by the International Organization for Migration reveal that more than 6,600 Africans have perished over the period of five years, while crossing the Sahara desert into Libya. The report specifies that the numbers are "just the tip of the iceberg."
There'll never be peace in this country, until… —Ango…
Zamfara governor knows he can't win second term, except……
South-West govs have no reason to fear anyone —Arogbofa,…
Human trafficking is a high profit business, which presents low risk to the traffickers. They seek victims that are vulnerable and uninformed about irregular migration, victims who suffer economic difficulties and are emotionally or psychologically susceptible. The trafficking and smuggling business is a primary source of earning. It is as old as time, and has become buoyant, and rebrands itself when necessary, restructuring its strategies.
My mother is hale and hearty ― Taye Currency
Nigeria has been recognized as one of the countries having the highest number of trafficking victims overseas (particularly in Libya and Europe), with victims identified in over 40 countries in 2017.
A UNICEF report revealed that the levels of sexual violence, exploitation, abuse and detention along the Central Mediterranean migration route makes it "among the world's deadliest and most dangerous migrant routes for children and women."
Still, many risk their lives daily to make the journey to Europe. AzuifeChillian was one of such people, who, without prior information about her journey, embarked on it, heading towards France. As a single mother, life was tough for her. She had been forced to drop out of the university in her final year because of certain difficulties. When the opportunity presented itself for her to leave the country in search of a better life, Chillian jumped at it without a second thought. She was to find out much later, that she had made a huge mistake.
Chillian shares her story in this eye-opening interview.
What influenced your decision to take the trip?
It was because of the academics. As at the time I discovered there was nothing else I could do, I was moved and felt if I leave the country and go out there, I'll be able to study again. Also, things became difficult in my family. A lot of financial challenges and I have a son. So, when I looked at the challenges I had and the responsibilities, I decided to travel.
Whom did you ask for help to leave Nigeria?
I didn't actually approach any agent. It was my cousins outside the country. I have two cousins in France and one in Italy. The ones in France sent message home that they needed four persons from the country they wanted to assist but on a condition. Once you come over and you start working, you would pay them N8million. I was interested because I was confident that whatever job I get there, I would use it to offset the bill.
How easy was it sourcing for funds for the trip?
The only money I put together was the money I used to travel from Delta to Benin to meet my cousin who was preparing for the journey. Also, money for feeding because I was told that the journey would take few days.
Tell us about your journey. Where did it commence?
I left from Benin to Kano. Initially, we were told we were leaving from Benin to Abuja but when we got to Abuja because they had already taken our phones away, I couldn't reach my family. It was when we got to Kano that I discovered that it was an illegal journey. The guys we met first gave us hijab to cover ourselves, to pretend that we were Muslims. I started noticing funny movements. They put us on a bike to take us to the border. The movement of the bike men, avoiding the police, not using the right paths, going through the bushes, made it all suspicious. At some point, they took us to a building where they hid us until the evening.
It looked like they already had a vehicle arranged. They took us back to the border. When we got there, we were searched. Before this, they had given us fake documents. Mine was bearing my picture but not my name. The smugglers said I was already there and couldn't do anything. If I spoke too much, they would lock me up. So, I had to stay silent.
At the border, they checked our documents. I had to cram my fake name. When I was asked what name was on the paper, I recited it. Our papers were given to us and we were asked to leave.
When we got to where the vehicle was, we were about 30 or more in a small vehicle. I had to sit in the boot. I didn't have any choice. We were treated like animals. I was a bit confused but I was just watching.
They moved us. They were still avoiding the police as they approached the next country. They got to a certain point. They dropped everyone and ran off. We were asking what was wrong but no one answered. An hour later, another vehicle came. They started calling passengers. The man amongst four of us knew whose passenger we were because he already knew the route. They put us in the vehicle. Two days later, we got to Agadez where we spent three days. They moved us to another building that was worse than where we were before.
They told us to get ready to leave and get water ready. I was wondering why we needed water because they asked us to get a big keg. We had to sell the phone we had to buy the keg, so no more communication. They prepared us and brought a Hilux truck. From the connection we used, we had about nine trucks that left that venue through the desert. Each Hilux had about 30 people. They gave us sticks around the truck to hold so that you don't fall off.
The people sitting inside suffered the most because there was no air. You are sitting tightly and you can't tell anyone to adjust because there is no space. We had water pouring on our bodies. I sat on the keg of fuel and got burnt, but I couldn't do anything. I treated it during the next stop with olive oil.
I spent a month and three weeks in the desert. They kept handing us from one driver to another. At some point, we were caught by the police in the desert and taken back to Dirkou. We were held for four days. On the fourth day, they told us they would take us back to Nigeria. My friends with me reasoned together and said, "How can we be this crazy to go back through the same means we came? We've already suffered. We've passed through a lot. We have to run."
It wasn't easy for me. I was thinking, the first time we were caught, I saw guns with my eyes. I was scared that if they caught us again, who knows what they would do to us. The guys said, "Don't worry. You'll be fine." So, we had to run. Then we ran into trouble.
We met another driver who told us he would help us. We jumped into his vehicle and he sold us. We had no idea. From there, we were taken to Libya. In Qatrun, an Igbo man bought us.
What was your experience in Libya?
Before we left Nigeria, we were given garri without sugar or milk, and a packet of cabin biscuit. Before one month, it finished. The major problem I had was water. I am someone who endures hunger. My problem basically was water. It got to a point, I almost fainted. I was crying and was also losing strength. After about 30 minutes, I noticed I wasn't seeing clearly. I knew something was happening to me. But the driver came to our rescue and gave us water.
Now, at Qatrun, the Igbo man took us to his house, gave us water to bathe and welcomed us to Libya like he was friendly. So, I felt at ease, but I never knew that it was trouble calling. I heard him talk to someone in Igbo and knew he was Igbo. After three hours of getting there, he called us to sit around him.
"Do you know why you're in Libya?" he asked. I didn't know why I was in Libya because that was not my destination country. I didn't say anything. We were all looking at him. At some point, he gave a signal to one of the guys standing beside him. They went upstairs and brought guns. The man had a lot of guns. Real big guns. I was surprised. They gave him one and he shot into the air. In the room. Because there is a way Libyan buildings are. They have strong walls. It took me about 3-5 minutes to recover from the shock of the shot. I was the first to say I know why I was in Libya. Because of the shock of the shot.
He gave us few hours to get N300, 000. He threatened that if we didn't bring the money within the duration he gave us, he was going to sell the ladies into prostitution. And for the guys, it was whatever.
I knew this was trouble. We had to start calling and they sent the money to bail us. Once they gave us the money, he moved us from his house to Sabha to meet the connection man, because once you pay your money, you're free to go. The connection man took care of us for about two days, but I got uncomfortable and told them I wanted to go, because I had noticed some funny movement. I didn't know what the man had planned for us.
The man acknowledge that he knew we wanted to go, but we had to wait for a while because they were having some issues at the Mediterranean seaside. But out of stubbornness, I insisted.
He said, "You know you're very stubborn. Calm down. There's a reason why I'm saying you should wait."
I told my cousin that if they don't move us, I'll raise an alarm. They said it wasn't safe, so they had to move us.
From Sabha to the seaside, Sabratha, took four days. They had to wait for passengers.
I saw a lot of things, especially one night when a guy from Sudan brought five dinar. I was sleeping, covering myself. Someone was tapping me. I woke up and looked at him giving me five dinar to sleep with me. That is about N500. I screamed and it woke everyone up. They asked what was going and I told them. They shouted on him.
I really saw a lot of things; so many of our ladies, because of hunger or one or two difficulties would give in to those men. These things made me angry and restless. I just wanted to leave Libya. One other thing I discovered how unsafe it was for pregnant women. Some of them delivered in such situations.
I was devastated. I was feeling so sad. I was always crying. I was not happy until we go to the seaside. At the seaside, we spent one month and a few days. No pushing. They said whenever they push people to the sea; they catch the boat and send them back to Libya. Because of that, the connection men told us to wait. So, few days later, the Libyan police came and arrested all of us and detained us.
I was in prison for three months. It was horrible. No food. No good food. At first, we were more than 4000 in my cell, so it wasn't easy to feed. There's a type of bread they have in Libya. A loaf of it cannot feed a baby, but we were made to share three-to-one, two-to-one. And then, at some point, they started preparing rice, sometimes macaroni. Food that you give to the dog. I don't know how they mix it. They just mix it and bring it. Sometimes, I won't be able to eat it. Sometimes, if I eat their rice, for three days I won't recover because of sore throat; we faced a lot of difficulties.
And then, they treat black Africans like animals. The way they talk to you, when they want to tell you to sit down. They don't even say it. They beat you. So, it was really difficult.
How did you return? Did you get help from anyone?
We didn't contact anyone. The International Organization for Migration came to visit us and asked who was interested in going back home to Nigeria. I registered and then they brought us back home.
How was the reception at home when you got back?
The reception from home, from my family was warm. My mom was so happy. She was already lean, probably from frustration from the fact that I was no longer there and they couldn't hear from me. They could no longer hear from me. And my dad, he actually shed tears. He said thank God I didn't die, because he thought that something had gone wrong. And then my two siblings were so happy that I had returned to the country.
What advice do you have for those intending to travel out of Nigeria?
First of all, I like telling them to travel for the right reasons because a lot of us travel because of finance. That's not a good reason to travel. You should have what you actually want to achieve where you're going to. And then, I also tell them to make sure they have their documents so that they can have the right migrant's protection. If you go into the country without a regular permit, you're at risk and there's nobody seeing to the fact that you're safe. So, I'm advising our youths: How about building our country? It's our responsibility.
An Italian lady told me if all the brainy and intelligent people in Nigeria should leave, who would build the country? So, we don't have to start running off because there is hardship. We have to look at what we can do to proffer solution to what we are passing through.
Also, I want to encourage youths to stay informed. My problem started with lack of information. I was the type that never bothered going online to get information. I never knew that there was a journey through the desert and the Mediterranean Sea. There was a time my sister mentioned something about a baby and a mother surviving on a boat on the Mediterranean, I asked her, "What were they thinking?" I never knew that someday I would be a victim.
Youths, stay informed. Don't say "I'm in the village." Even if you're in the village, you need information to grow. The only thing that can cause you problem is to detach yourself from sources of information. So, youths, try and build yourself; it helps. I never believed in it but today I'm talking about it.
Chillian is a social worker and an advocate today. With the help of some NGOs, she goes to schools to enlighten people on the dangers of irregular migration. She says she finds joy in disseminating the information. She doesn't want Nigerian youths getting into trouble the way she did.
$1.1bn needed for Nigeria/Brazil agriculture project — Minister
Massive shake-up in Army, Adeosun, 50 other Generals redeployed
FUNKE OLAKUNRIN'S KILLING: Those who shot us were not robbers
There'll never be peace in this country, until... —Ango Abdullahi
BREAKING: Obasanjo raises security alarm in another open letter to Buhari [FULL TEXT]
Oyo: Seyi Makinde publicly declares assets worth over N48 billion
I don't see patriotism in Obasanjo's letters ― Yakassai
Sexual assault: Uproar as CAN declares support for Biodun Fatoyinbo during visit to COZA + VIDEO
JUST IN: Sanwo-Olu names 25 commissioners, advisers, returns ex-SSG, Tunji Bello
Anike's Diary
Autoclinic With The Mechanic
Awo's Thought
Crucial Moment
Empowered For Life
Festus Adebayo's Flickers
Financewise
Gibbers
Language & Style
Leaders' Forum
Lynx Eye
Monday Lines
Mum & Child
Notes from Atlanta with Farooq Kperogi
On The Lord's Day
Political Panorama
Veritatem With Obadiah Mailafia
Voice of Courage
Whatsapp Conversation
You and Eye
Your Life Counts
Arewa
Islamic News
Eye of Islam
Tribune Church
Ecoscope
Property & Environment
Info Tech
Arewa Live
Arts & Reviews
Campus Beat
Event Digest
Sexuality & Health
Travelpulse & MICE
Tribune Business
Weekend Lagos
Home – Breaking News In Nigeria Today – Tribune Online
Tribune Advertisement Rates
© 2019 - Tribune Online. All Rights Reserved.


text:
Gander Fire Rescue opens new hall
July 29, 2011, Gander, N.L. - The Town of Gander, N.L., celebrated the official opening of its new fire hall on Friday.
July 29, 2011 By Carey Fredericks
According to a press release from Infrastructure Canada, the new hall
was designed with the future in mind. The building is 1,330 square
metres and is located to service the projected growth of the
municipality. The building's main features include increased space to
house longer ladders, a hazardous materials trailer, offices, training
rooms and an emergency operations centre.
The federal government provided $1.6 million in infrastructure funding for the $5-million project.
The Town of Gander, N.L., celebrated the opening Friday of its new, $5.2 million Gander Fire Rescue hall, which was funded by all three levels of government. Photo by Paula Clark.
"Our government is proud to have invested in Gander's new fire hall. This project not only created jobs, but will allow Gander firefighters to effectively and safely carry out their work," said Intergovernmental Affairs Minister Peter Penashue. "Most importantly though, today we are celebrating an exciting project that will help to keep Gander safe for many years to come."
Newfoundland and Labardor Premier Kathy Dunderdale, who was in Gander recently to attend the Newfoundland and Labrador Association of Fire Services conference and was at the station opening on Friday, said the new hall will serve both the firefighters who work at the facility and area residents. "Our government has been pleased to partner with both the Government of Canada and the Town of Gander to make this project a reality, and I look forward to the many years of fire and emergency response capability this facility will provide."
Gander Mayor Claude Elliott said the new hall recognized the needs of a modern fire service and the importance of up-to-date equipment.
"It's about the future," he said. "The science and technology of firefighting has changed dramatically over the past few decades, and so have the make-up and the role of the department itself. This beautiful new building is not only designed to accommodate these new realities, but also to grow with our community and to provide the flexibility to adapt as technologies and methods continue to evolve. We are extremely proud of the men and women of Gander Fire Rescue and it gives me great pleasure to be able to provide a facility that reflects the professionalism and dedication that they bring to the job every day."
The Government of Canada contributed about $1.7 million to the new hall under the Infrastructure Stimulus Fund. The Government of Newfoundland and Labrador contributed more than $1.8 million and the Town of Gander contributed $1.5 million. Total cost of the project is $5.2 million.
BBQ may be to blame for house fire
Moncton rescue crews test new hovercraft
Ice buildup causes Calgary condo to fill with carbon monoxide
Man arrested in connection with rash of vehicle fires
Fighting fire with public awareness
The Red Rock Volunteer Fire Department


text:
Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019
RARITAN, N.J., Sept. 17, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from its prostate cancer and solid tumor portfolios will be featured at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain. Among Janssen's 12 accepted abstracts are an oral presentation reporting updated overall survival results from the ERLEADA® (apalutamide) Phase 3 SPARTAN study in patients with non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the ERLEADA® Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC), demonstrating preservation of overall health-related quality of life; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD).
"Janssen is focused on addressing areas of unmet need in both prostate cancer and solid tumors, and this year's ESMO Annual Congress provides an opportunity to share these important study results for both approved and investigational therapies," said Mark Wildgust, Ph.D., Vice President, Global Medical Affairs, Oncology, Janssen Research & Development, LLC. "In particular, we look forward to presenting new data for ERLEADA® and niraparib, which reinforce our continued commitment to improve outcomes for patients diagnosed with prostate cancer across the disease spectrum."
Company-sponsored abstracts to be presented at the meeting include:
Abstract No.
ERLEADA® (apalutamide)
Abstract #843O
Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Updated Results from the Phase 3 SPARTAN Study
2:39 PM - 2:51 PM CET
Abstract #851PD
Patient-Reported Outcomes (PROs) From TITAN: A Phase 3, Randomized, Double-Blind Study of Apalutamide Versus Placebo
Added to Androgen Deprivation Therapy in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
12:00 PM CET
Abstract #883P
Androgen Receptor Aberrations in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated with Apalutamide Plus Androgen Deprivation Therapy in TITAN
Abstract #900TiP
A Phase 2 randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy
Niraparib
Abstract #LBA50
Pre-specified interim analysis of GALAHAD: A Phase 2 study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects
8:30 AM CET
A Phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Abstract #1412P
Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib
ZYTIGA® (abiraterone acetate)
Abstract #95P
Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
BALVERSA™ (erdafitinib)
Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients with metastatic urothelial carcinoma
Erdafitinib versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Antitumor Activity Among Patients with Advanced Urothelial Carcinoma
Solid Tumor Portfolio
Correlation of Progression Free Survival-2 and Overall Survival in Solid Tumors
2:00 PM CET
About ERLEADA® (apalutamide)
ERLEADA® (apalutamide) is an androgen receptor (AR) inhibitor indicated for the treatment of patients with nmCRPC.1 It became the first treatment to receive FDA approval for nmCRPC on February 14, 2018.1 ERLEADA® was also approved for the treatment of nmCRPC by the European Commission on January 12, 2019. ERLEADA® is being studied in five Phase 3 registrational clinical trials. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer include apalutamide as a treatment option for patients with non-metastatic (M0) CRPC with a category 1 recommendation for those with a PSA doubling time ≤10 months*.2 Similarly, the American Urological Association (AUA) Guidelines for Castration-Resistant Prostate Cancer (CRPC) recommend clinicians offer apalutamide (ERLEADA®) with continued androgen deprivation therapy (ADT) as one of the treatment options for patients with nmCRPC at high risk for developing metastatic disease. (Standard; Evidence Level Grade A)**.3 ERLEADA® is taken orally, once daily, with or without food.1
*Referenced from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed September 5, 2019. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way
**Standard: Directive statement that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be taken based on Grade A or B evidence.
**Evidence Level: A designation indicating the certainty of the results as high, moderate, or low (A, B, or C, respectively) based on AUA nomenclature and methodology.
About Niraparib
Niraparib is an orally-administered selective poly ADP ribose polymerase (PARP) inhibitor that is currently being studied by Janssen for the treatment of patients with prostate cancer. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc., for exclusive rights to niraparib in prostate cancer. In the U.S., niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.4 Niraparib is currently marketed as ZEJULA® by TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facing cancer. Please refer to the full Prescribing Information available at https://www.zejula.com/prescribing-information.
About ZYTIGA® (abiraterone acetate)
ZYTIGA® (abiraterone acetate) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), approved by the U.S. FDA on April 28, 2011 and by the European Commission on September 7, 2011. Additionally, ZYTIGA® was approved for the treatment of high-risk metastatic castration-sensitive prostate cancer (mCSPC) by the European Commission on November 20, 2017 and by the U.S. FDA on February 8, 2018. Since its first approval in the U.S. in 2011, ZYTIGA® has been approved in combination with prednisone or prednisolone, in more than 100 countries. More than 500,000 patients worldwide have been prescribed ZYTIGA®.
About BALVERSATM (erdafitinib)
BALVERSA™ (erdafitinib) is a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) that has susceptible FGFR3 or FGFR2 genetic alterations and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.5 In 2008, Janssen entered into an exclusive worldwide license and collaboration agreement with Astex Pharmaceuticals to develop and commercialize BALVERSA™. This indication was approved by the U.S. FDA on April 12, 2019 under an accelerated approval based on tumor response rate. Patients may be suitable for BALVERSA based on an FDA-approved companion diagnostic. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.4
For more information about BALVERSA™, visit www.BALVERSA.com.
ERLEADA™ IMPORTANT SAFETY INFORMATION
Pregnancy — ERLEADA™ (apalutamide) can cause fetal harm and potential loss of pregnancy.
Falls and Fractures — In a randomized study (SPARTAN), falls and fractures occurred in 16% and 12% of patients treated with ERLEADA™ compared to 9% and 7% treated with placebo, respectively. Falls were not associated with loss of consciousness or seizure. Evaluate patients for fracture and fall risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone targeted agents.
Seizure — In a randomized study (SPARTAN), 2 patients (0.2%) treated with ERLEADA™ experienced a seizure. Permanently discontinue ERLEADA™ in patients who develop a seizure during treatment. It is unknown whether anti-epileptic medications will prevent seizures with ERLEADA™. Advise patients of the risk of developing a seizure while receiving ERLEADA™ and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others.
Adverse Reactions — The most common adverse reactions (≥10%) were fatigue, hypertension, rash, diarrhea, nausea, weight decreased, arthralgia, fall, hot flush, decreased appetite, fracture, and peripheral edema.
Laboratory Abnormalities — All Grades (Grade 3-4)
Hematology — anemia ERLEADA™ 70% (0.4%), placebo 64% (0.5%); leukopenia ERLEADA™ 47% (0.3%), placebo 29% (0%); lymphopenia ERLEADA™ 41% (2%), placebo 21% (2%)
Chemistry — hypercholesterolemia ERLEADA™ 76% (0.1%), placebo 46% (0%); hyperglycemia ERLEADA™ 70% (2%), placebo 59% (1%); hypertriglyceridemia ERLEADA™ 67% (2%), placebo 49% (0.8%); hyperkalemia ERLEADA™ 32% (2%), placebo 22% (0.5%)
Rash — Rash was most commonly described as macular or maculo-papular. Adverse reactions were 24% with ERLEADA™ versus 6% with placebo. Grade 3 rashes (defined as covering > 30% body surface area [BSA]) were reported with ERLEADA™ treatment (5%) versus placebo (0.3%).
The onset of rash occurred at a median of 82 days. Rash resolved in 81% of patients within a median of 60 days (range: 2 to 709 days) from onset of rash. Four percent of patients treated with ERLEADA™ received systemic corticosteroids. Rash recurred in approximately half of patients who were re-challenged with ERLEADA™.
Hypothyroidism was reported for 8% of patients treated with ERLEADA™ and 2% of patients treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months. Elevated TSH occurred in 25% of patients treated with ERLEADA™ and 7% of patients treated with placebo. The median onset was day 113. There were no Grade 3 or 4 adverse reactions. Thyroid replacement therapy, when clinically indicated, should be initiated or dose-adjusted.
Effect of Other Drugs on ERLEADA™ — Co-administration of a strong CYP2C8 or CYP3A4 inhibitor is predicted to increase the steady-state exposure of the active moieties. No initial dose adjustment is necessary; however, reduce the ERLEADA™ dose based on tolerability [see Dosage and Administration (2.2)].
Effect of ERLEADA™ on Other Drugs — ERLEADA™ is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9 in humans. Concomitant use of ERLEADA™ with medications that are primarily metabolized by CYP3A4, CYP2C19, or CYP2C9 can result in lower exposure to these medications. Substitution for these medications is recommended when possible or evaluate for loss of activity if medication is continued. Concomitant administration of ERLEADA™ with medications that are substrates of UDP-glucuronosyl transferase (UGT) can result in decreased exposure. Use caution if substrates of UGT must be co-administered with ERLEADA™ and evaluate for loss of activity.
P-gp, BCRP or OATP1B1 substrates — Apalutamide is a weak inducer of P-glycoprotein (P- gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically. Concomitant use of ERLEADA™ with medications that are substrates of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. Use caution if substrates of P-gp, BCRP or OATP1B1 must be co-administered with ERLEADA™ and evaluate for loss of activity if medication is continued.
Please see the full Prescribing Information for ERLEADA™.
ZYTIGA® IMPORTANT SAFETY INFORMATION
Hypokalemia, Fluid Retention, and Cardiovascular Adverse Reactions due to Mineralocorticoid Excess - ZYTIGA® may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition [see Clinical Pharmacology (12.1)]. Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month. Control hypertension and correct hypokalemia before and during treatment.
Closely monitor patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia, or fluid retention, such as those with heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia. In postmarketing experience, QT prolongation, and torsades de pointes have been observed in patients who develop hypokalemia while taking ZYTIGA®. The safety of ZYTIGA® in patients with left ventricular ejection fraction <50% or New York Heart Association (NYHA) Class III or IV heart failure (in COU-AA-301) or NYHA Class II to IV heart failure (in COU-AA-302 and LATITUDE) has not been established because these patients were excluded from these randomized clinical trials [see Clinical Studies (14)].
Adrenocortical Insufficiency - Adrenocortical insufficiency was reported in patients receiving ZYTIGA® in combination with prednisone, after an interruption of daily steroids and/or with concurrent infection or stress. Monitor patients for symptoms and signs of adrenocortical insufficiency if prednisone is stopped or withdrawn, if the prednisone dose is reduced, or if the patient experiences unusual stress. Symptoms and signs of adrenocortical insufficiency may be masked by adverse reactions associated with mineralocorticoid excess seen in patients treated with ZYTIGA®. Perform appropriate tests, if clinically indicated, to confirm adrenocortical insufficiency. Increased dosages of corticosteroids may be used before, during, and after stressful situations [see Warnings and Precautions (5.1)].
Hepatotoxicity - In postmarketing experience, there have been ZYTIGA®-associated severe hepatic toxicities, including fulminant hepatitis, acute liver failure, and deaths. Measure serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment with ZYTIGA®, every two weeks for the first three months of treatment, and monthly thereafter. In patients with baseline moderate hepatic impairment receiving a reduced ZYTIGA® dose of 250 mg, measure ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, every two weeks for the following two months of treatment, and monthly thereafter. Promptly measure serum total bilirubin, AST, and ALT if clinical symptoms or signs suggestive of hepatotoxicity develop. Elevations of AST, ALT, or bilirubin from the patient's baseline should prompt more frequent monitoring. If at any time AST or ALT rise above five times the upper limit of normal (ULN) or the bilirubin rises above three times the ULN, interrupt ZYTIGA® treatment and closely monitor liver function. Re-treatment with ZYTIGA® at a reduced dose level may take place only after return of liver function tests to the patient's baseline or to AST and ALT less than or equal to 2.5X ULN and total bilirubin less than or equal to 1.5X ULN [see Dosage and Administration (2.4)].
Permanently discontinue ZYTIGA® for patients who develop a concurrent elevation of ALT greater than 3X ULN and total bilirubin greater than 2X ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation.
The safety of ZYTIGA® re-treatment of patients who develop AST or ALT greater than or equal to 20X ULN and/or bilirubin greater than or equal to 10X ULN is unknown.
Increased Fractures and Mortality in Combination with Radium Ra 223 Dichloride - ZYTIGA® plus prednisone/prednisolone is not recommended for use in combination with radium Ra 223 dichloride outside of clinical trials. Increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received ZYTIGA® plus prednisone/prednisolone in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with ZYTIGA® plus prednisone/prednisolone [see Warnings and Precautions (5.4)].
Embryo-Fetal Toxicity - The safety and efficacy of ZYTIGA® have not been established in females. Based on animal reproductive studies and mechanism of action, ZYTIGA® can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment with ZYTIGA® and for 3 weeks after the last dose of ZYTIGA®[see Use in Specific Populations (8.1, 8.3)]. ZYTIGA® should not be handled by females who are or may become pregnant [see How Supplied/Storage and Handling (16)].
Adverse Reactions - The most common adverse reactions (≥10%) are fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot flush, diarrhea, vomiting, upper respiratory tract infection, cough, and headache.
The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, and hypokalemia.
Drug Interactions - Based on in vitro data, ZYTIGA® is a substrate of CYP3A4. In a drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during ZYTIGA® treatment. If a strong CYP3A4 inducer must be co-administered, increase the ZYTIGA® dosing frequency only during the co-administration period [see Dosage and Administration (2.3)]. In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone.
ZYTIGA® is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. Avoid co-administration with CYP2D6 substrates with a narrow therapeutic index. If alternative treatments cannot be used, consider a dose reduction of the CYP2D6 substrate drug. In a CYP2C8 drug interaction trial in healthy subjects, the AUC of pioglitazone, a CYP2C8 substrate, was increased by 46% when administered with a single dose of ZYTIGA®. Patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA®.
Use in Specific Populations -
Females and Males of Reproductive Potential: Advise males with female partners of reproductive potential to use effective contraception.
Do not use ZYTIGA® in patients with baseline severe hepatic impairment (Child-Pugh Class C).
Please read the full Prescribing Information and Patient Information for ZYTIGA®.
BALVERSA™ IMPORTANT SAFETY INFORMATION
Ocular Disorders - BALVERSATM can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect.
CSR/RPED was reported in 25% of patients treated with BALVERSATM, with a median time to first onset of 50 days. Grade 3 CSR/RPED, involving central field of vision, was reported in 3% of patients. CSR/RPED resolved in 13% of patients and was ongoing in 13% of patients at the study cutoff. CSR/RPED led to dose interruptions and reductions in 9% and 14% of patients, respectively and 3% of patients discontinued BALVERSATM. Dry eye symptoms occurred in 28% of patients during treatment with BALVERSATM and were Grade 3 in 6% of patients. All patients should receive dry eye prophylaxis with ocular demulcents as needed.
Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms. Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography. Withhold BALVERSATM when CSR occurs and permanently discontinue if it does not resolve within 4 weeks or if Grade 4 in severity. For ocular adverse reactions, follow the dose modification guidelines [see Dosage and Administration (2.3)].
Hyperphosphatemia - Increases in phosphate levels are a pharmacodynamic effect of BALVERSA™ [see Pharmacodynamics (12.2)]. Hyperphosphatemia was reported as adverse reaction in 76% of patients treated with BALVERSA™. The median onset time for any grade event of hyperphosphatemia was 20 days (range: 8-116) after initiating BALVERSA™. Thirty-two percent of patients received phosphate binders during treatment with BALVERSA™. Monitor for hyperphosphatemia and follow the dose modification guidelines when required [see Dosage and Administration (2.2, 2.3)].
Embryo-fetal Toxicity - Based on the mechanism of action and findings in animal reproduction studies, BALVERSA™ can cause fetal harm when administered to a pregnant woman. In a rat embryo-fetal toxicity study, erdafitinib was embryotoxic and teratogenic at exposures less than the human exposures at all doses studied. Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception prior to and during treatment, and for one month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with BALVERSA™ and for one month after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].
Most common adverse reactions including laboratory abnormalities > 20% were: Phosphate increased (76%), stomatitis (56%), fatigue (54%), creatinine increased (52%), diarrhea (47%), dry mouth (45%), onycholysis (41%), alanine aminotransferase increased (41%), alkaline phosphatase increased (41%), sodium decreased (40%), decreased appetite (38%), albumin decreased (37%), dysgeusia (37%), hemoglobin decreased (35%), dry skin (34%), aspartate aminotransferase increased (30%), magnesium decreased (30%), dry eye (28%), alopecia (26%), palmar-plantar erythrodysesthesia syndrome (26%), constipation (28%), phosphate decreased (24%), abdominal pain (23%), calcium increased (22%), nausea (21%), and musculoskeletal pain (20%). The most common Grade 3 or greater adverse reactions (>1%) were stomatitis (9%), nail dystrophy*, palmar-plantar erythrodysesthesia syndrome (6%), paronychia (3%), nail disorder*, keratitis†, onycholysis* (10%), and hyperphosphatemia.
*Included within onycholysis. ^Included within dry eye.
An adverse reaction with a fatal outcome in 1% of patients was acute myocardial infarction.
Serious adverse reactions occurred in 41% of patients, including eye disorders (10%).
Permanent discontinuation due to an adverse reaction occurred in 13% of patients. The most frequent reasons for permanent discontinuation included eye disorders (6%).
Dosage interruptions occurred in 68% of patients. The most frequent adverse reactions requiring dosage interruption included hyperphosphatemia (24%), stomatitis (17%), eye disorders (17%), and palmar-plantar erythrodysesthesia syndrome (8%).
Dose reductions occurred in 53% of patients. The most frequent adverse reactions for dose reductions included eye disorders (23%), stomatitis (15%), hyperphosphatemia (7%), palmar-plantar erythrodysesthesia syndrome (7%), paronychia (7%), and nail dystrophy (6%).
Strong CYP2C9 or CYP3A4 Inhibitors: Consider alternative agents or monitor closely for adverse reactions. (7.1)
Strong CYP2C9 or CYP3A4 inducers: Avoid concomitant use with BALVERSA™. (7.1)
Moderate CYP2C9 or CYP3A4 inducers: Increase BALVERSA™ dose up to 9 mg. (7.1)
Serum phosphate level-altering agents: Avoid concomitant use with agents that can alter serum phosphate levels before the initial dose modification period. (2.3, 7.1)
CYP3A4 substrates: Avoid concomitant use with sensitive CYP3A4 substrates with narrow therapeutic indices. (7.2)
OCT2 substrates: Consider alternative agents or consider reducing the dose of OCT2 substrates based on tolerability. (7.2)
P-gp substrates: Separate BALVERSA™ administration by at least 6 hours before or after administration of P-gp substrates with narrow therapeutic indices. (7.2)
Lactation – Because of the potential for serious adverse reactions from erdafitinib in a breastfed child, advise lactating women not to breastfeed during treatment with BALVERSATM and for one month following the last dose.
Please click here for full prescribing information.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding potential benefits and further benefits of ERLEADA® ZYTIGA®, BALVERSATM and niraparib. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
1 ERLEADA U.S. Prescribing Information, February 2018.
2 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Updated August, 2019.
3 American Urological Association. Castration-Resistant Prostate Cancer Guidelines. http://www.auanet.org/guidelines/castration-resistant-prostate-cancer-(2013-amended-2018). Accessed September 2019.
4 Niraparib U.S. Prescribing Information, June 2019.
5 BALVERSA U.S. Prescribing Information, April 2019.
Suzanne Frost
Brian Kenney
Christopher DelOrefice
Lesley Fishman
U.S. Medical Inquiries:
View original content:http://www.prnewswire.com/news-releases/janssen-to-highlight-depth-of-prostate-cancer-and-solid-tumor-portfolios-with-multiple-data-presentations-at-esmo-2019-300919622.html
SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson
Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
BALVERSA(TM) (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer


Can't leave Europe without doing… ?
First experience in Europe. Traveling with 9 other friends to explore what Europe has to offer. Would love to know your absolute best must dos, best eateries, and best sightseeing in London, Paris, and Berlin.
First of all, if this is your first time in Europe, you must do the touristy things... they landed on the tourist track for a reason! In Paris, do not miss: the Eiffel Tower, Notre-Dame de Paris, Sacre Coeur & Montmartre, Louvres, the Musée d'Orsay, Les Invalides, and a walk along the La Seine. Go out of town & see Versailles & Giverny.
In London: get on the hop-on, hop-off Big Red Bus. This will give you an overview of London, & then you can go back & visit the things that strike your fancy. Personally I love the Tower Of London & its history. Then there is Saint Paul's Cathedral, the House Of Commons, Westminster Abbey, Tower Bridge, Trafalgar Square. Churchill's War Rooms are amazing! If you are a Beatles fan, find the Abbey Rd crosswalk; if you are a Sherlock Holmes fan, go to 222 Baker St. Kew Gardens if you like gardens. Leicester Square if you want to take in a show. Greenwich, if you are interested in astronomy. Other than that, just wander around & soak up history by osmosis.
Sorry... I can't speak of Berlin.
On a warm summer night, amazing views and drinks at Sky Lounge's outdoor balcony DoubleTree by Hilton Hotel London - Tower of London overlooking Tower Bridge.
For Paris, I would recommend also to just have a walk around the small streets of the Quartier Du Marais and of the Saint-Germain-des-Prés area. It will get you out of the tourist flow and around some really nice bars, shops etc. Also in Paris, if you're a fan of real authentic Italian food I can recommend the Settebello at 9 Rue Duban, you have to reserve, it's quite pricy, but so worth it.
If you are a foodie then you need to take in London's burgeoning street food & food market scene. It is awesome! A particular recommendation is to go to Brixton Village and also Brixton Market which are my local culinary fixes. They are full of small, reasonably priced independent restaurants including Honest Burgers and Franco Manca. Each place could lay claim to being the best burger and pizza in the city respectively. Loads more in there including great pakistani curries at Elephant. Brixton is good area to visit in any case, off the tourist trail and has a vibrant atmosphere with a big Caribbean influence. You will not be bored!
Berlin - Take a walking tour from Hackescher Marktto get some history from a usually entertaining host. Visit the Holocaust Memorial, Museum Island, take a boat cruise along the spree to take in the architekture. Sammlung Boros is a private art collection housed in an above ground bunker in Mitte, you have to book a tour in advance (via their website) highly recommended! Spend an evening in the little bars around Weserstraße. If you're into club music visit Berghain. Spend Sunday shopping at MauerPark flea market then see the remaining Berlin Wall nearby. If you have time visit the Bauhaus Archive, New National Gallery & Potsdamer Platz and the Bundestag. Have fun!


text:
Q: why '&' changes the behaviour of the object? I'm studying C++ form Thinking in C++ V1. I came across an example that demonstrates inheritance. Here it goes
#include <iostream>

class Instrument{
public:
    virtual void play(){
        std::cout<<"instrument::play()";
    }
};

class Wind: public Instrument{
public:
    void play(){
        std::cout<<"Wind::play()";
    }
};

void tune(Instrument& i){
    i.play();
}
int _tmain(int argc, _TCHAR* argv[])
{
    Wind flute;
    tune(flute);
    return 0;
}

This outputs Wind::play() on the console.
But if I change the method 'tune' to
void tune(Instrument i){
    i.play();
}

The output will instrument::play()
Since the '&' is added so that the reference of flute is passed instead of a copy, why does the program output instrument::play() instead of Wind::play() ?

A: The polymorphic behavior of an object expression in C++ is determined by its dynamic type.

*

*When you attach a reference of type Instrument &i to an object of type Wind, the dynamic type of the object referred by i is preserved. I.e. even though i is declared with type Instrument, it actually refers to an actual object of type Wind. And that is why i continues to behave as Wind. The same would be true if you refer to some object with a pointer.
Speaking in formal language, it means that static type of expression i is Instrument, but dynamic type if the same expression is Wind. For this reason, i behaves polymorphically as Wind.

*Meanwhile, when you assign (or initialize) an object Instrument i with a value of type Wind, you create an independent standalone object i of type Instrument. The type of this object is Instrument. So that standalone copy i will behave as Instrument in all polymorphic contexts.
Again, speaking in formal language, it means that in this case both static type and dynamic type of expression i is Instrument. For this reason, i behaves polymorphically as Instrument.
In C++ language the only way to "preserve" a dynamic type of the object is to refer to that object with pointers or references. "Refer" is the key word here: you do not create new objects, but rather  refer to already existing objects. And those existing objects continue to behave in accordance with their native type. An object of type Wind continues to behave as an object of type Wind. (Note that this applies to polymorphic behavior only, e.g. to how virtual function calls are resolved.)
But whenever you create an independent copy of an object (instead of referring to the original), that copy acquires a life of its own, with its own type and related properties. A standalone copy of type Instrument has no relation to the original Wind object. It has no memory of the fact that it was born as a copy of a Wind object. It behaves as an Instrument.

A: This is the problem called "slicing". When you copy Wind into an Instrument it becomes an Instrument.

A: Because the copy that gets passed has type Instrument, not type Wind, because Instrument is the type that the function takes. This is known as "slicing".

A: In
void tune(Instrument i){
    i.play();
}

You create a new instance if the Instrument object, and the Instrument object will print instrument::play
When you used the reference operator & you referred to an existing object that was of the Wind type.

A: The reason that the Instrument::play function is called, is because when you pass a copy, it's actually the Instrument part of the object you pass, since you slice the object.


Fiddler's Green Amphitheatre is the largest outdoor amphitheater in the Denver metropolitan area. With 7,000 reserved seats as well as a lawn that can hold up to 10,000 guests, Fiddler's Green Amphitheatre is the premiere outdoor event space in Colorado.
Equipped with state-of-the-art stage, sound, and lighting equipment, the amphitheater is able to host a wide range of private events, theater productions, seminars, conferences, and trade shows. In addition, Fiddler's Green Amphitheatre has multiple spaces within the grounds that can accommodate a wide range of guest capacities.


text:
Scottish Outdoor Access Network > Resources > Links
Scottish Outdoor Access Code All you need to know about statutory access rights, responsibilities, and how to manage access.
Scottish Natural Heritage SNH Access pages, including the National Access Forum
The Paths for All Partnership Established to provide a national lead in creating and promoting path networks.
Scottish Countryside Rangers Association
Forestry Commission Scotland
Scottish Government The Executives pages on responsible public access and the Land Reform Act
SL&E Scottish Land & Estates represents the role and interests of those involved with rural property and businesses connected with the land.
NFU Scotland representing 10,000 farmers, crofters and growers the length and breadth of the country.
Central Scotland Green Network
Ramblers Ramblers Scotland is the representative body for walkers in Scotland. For over 75 years we have been campaigning in Great Britain to protect the natural beauty of our countryside, promote walking and safeguard public access to land.
The Scottish Access Technical Information Network was set up in 2009 to share good practice and to support people interested and involved in design, construction and maintenance of infrastructure for active travel, outdoor access and mountain biking. SATIN aims to develop, co-ordinate and promote the sharing of technical information and knowledge. This web site will facilitate the sharing of good practice, research and innovation, and networking and skills development to achieve excellence.


text:
North, South Korea reportedly discussing plan to announce end of war following summit
By Global News
Posted April 17, 2018 9:49 am
Updated April 17, 2018 7:07 pm
1:38 Trump says possible summit with North Korea's Kim Jong Un may not happen
WATCH ABOVE: U.S. President Donald Trump said Tuesday that North Korea and South Korea had his "blessing" as the two countries discuss ending the war. He also said if things don't go well, the meeting with Kim Jong Un may not happen.
North and South Korea are reportedly in talks to announce an end to the military standoff that has separated the countries since the Korean conflict some 68 years ago.
Next week, North Korean leader Kim Jong Un is scheduled to make history when he meets South Korean President Moon Jae In at a summit just inside South Korean territory across the fortified border that divides the two countries. He will be the first North Korean leader to step on South Korean soil since the 1950s.
South Korea's Yonhap News Agency reported Tuesday preparations are underway at the border truce village of Panmunjom for the April 27 summit between the two leaders, while President Moon expressed optimism, reaffirming his plan to establish peace on the Korean peninsula.
READ MORE: Japan's PM to meet with Donald Trump ahead of North Korea summits
"The complete denuclearization of the Korean Peninsula is the most urgent task that lies before us and a task we must complete peacefully," the news agency quoted the president as saying.
The Koreas technically remain at war as the 1950-1953 conflict ended in a truce, not a peace treaty.
WATCH: Trump says U.S. 'in direct talks' with North Korea ahead of summit with Kim Jong Un
1:15 Trump says U.S. 'in direct talks' with North Korea ahead of summit with Kim Jong Un
Trump says U.S. 'in direct talks' with North Korea ahead of summit with Kim Jong Un
Trump will attend annual anti-abortion 'March of Life' rally in Washington
Following the summit between the two Koreas, Kim is expected to meet with U.S. President Donald Trump as early as May to discuss possible denuclearization of the Korean peninsula.
"A North Korea-U.S. summit is scheduled to be held after the South-North Korea summit. A great transition that can create a new world order in the world history is beginning to take shape," Moon said.
READ MORE: North, South Korea talks underway to prepare for April summit
0:37 South Korea says officials may visit Pyongyang ahead of summit
South Korea says officials may visit Pyongyang ahead of summit
South Korean presidential chief of staff, Im Jong Sok, told reporters Tuesday the two Koreas hope to release a joint statement following next week's summit. Im said the statement would focus on denuclearization and peace on the peninsula.
Citing an unnamed South Korean official, newspaper Munwha Ilbo reported Tuesday, the joint statement would seek to ease the military standoff between the two countries.
WATCH: Japan's PM says Trump summit will focus on North Korea
0:46 Japan's PM says Trump summit will focus on North Korea
Japan's PM says Trump summit will focus on North Korea
However, Im expressed caution about the possible joint statement, noting that any agreement between the two countries would be hard to implement without the support of the U.S.
"This summit is significant because it will set the stage for the North Korea-U.S. summit, and even a possible three-way summit between the countries," Im told reporters. "Without U.S. support and agreement, it will be difficult to follow through on inter-Korean agreements."
READ MORE: Kim Jong Un says North Korea committed to denuclearization, China says
As for Moon, South Korea's goal for the upcoming summit is to establish permanent peace with the North.
"[The goal is] to bring down the wall between the South and the North and build a path to coexistence and joint development," Yonhap quoted the South Korean president as saying. "Separated families must be allowed to reunite, exchange greetings and freely visit each other."
WATCH: North Korea quiet as U.S. holds joint military drills with South Korea ahead of meeting
0:52 North Korea quiet as U.S. holds joint military drills with South Korea ahead of meeting
North Korea quiet as U.S. holds joint military drills with South Korea ahead of meeting
–With files from Reuters
Donald TrumpNorth KoreaKim Jong-UnSouth KoreaKorean WarMoon Jae-inNorth Korea weapons programKorea summitKorea peace treaty
94 Viewed
The Endnote
The best content straight to your inbox every Sunday


text:
Events (in German)
Main Exhibition "Traces of History"
Research Exhibition on the Camp SS
Slave Labour in Brick Production
Slave Labour in Armaments Production
Prison and Memorial
House of Remembrance
Slave Labour
Life in Camp
SS Guards
The Site after the War
Satellite Camps
Memorials in Hamburg
Death Register
Deaths 1940-1945
Guided Tours and Projects
Project Day
Particular projects
Education Partnerships
Vocational Schools and Professional Schools
Programmes for Vocational Schools and Professionals
Further Education and Seminars
Centre for Historical Studies
Education & Centre for Historical Studies
Archive request
About the Memorial
Tours for Individuals
Explore on Your Own
Volunteers at the Memorial
Friends of the Neuengamme Concentration Camp Memorial
Working Group Neuengamme
Church Volunteers at the Memorial
Action Reconciliation Service for Peace
Amicale Internationale KZ Neuengamme (AIN)
Current News (Blog)
Detail view of documents in the main exhibition. Photograph: Neuengamme Concentration Camp Memorial, 2013. (ANg 2014-458)
One of our tasks at Neuengamme Concentration Camp Memorial is to help initiate research projects on the history of Neuengamme and its satellite camps and to publish the results of this research. For this purpose, the Memorial cooperates with several partner universities, research institutes, museums, other memorials, history workshops and initiatives – especially those with a focus on the history of Neuengamme concentration camp and its satellite camps during and after the war. The Memorial regularly publishes the work of these research projects in Beiträge zur Geschichte der nationalsozialistischen Verfolgung in Norddeutschland, Neuengammer Kolloquien and Neuengammer Studienheften.
The following projects are currently underway in the Memorial's archive:
Completing the camp prisoner databases
Evaluating the custody lists of the former prisons
Comparing the camp's transport records and dates with those of other memorial archives
Researching the satellite camp system
Researching the history of the Neuengamme concentration camp's construction
The historical and art historical analysis of prisoners' drawings
Researching the SS guards stationed at Neuengamme concentration camp
International Conference "Survivors talk to their children" Photograph: Mark Mühlhaus, attenzione photographers, 2010. (ANg 2014-544)
The following projects are currently underway in the Centre for Historical Studies:
Assistance for visiting researchers and scholarship recipients who are staying for longer periods
Human rights and historical-political education for government employees (police officers, armed forces personnel, public administrators and the judiciary) in cooperation with academic and institutional partners.
Developing Competence-Orientated Teaching on Historical Memories (TeacMem)
Research project on Nazi perpetrators and how they have been dealt with in families and society
Research project focusing on concentration camp survivors and their children and how the experience of Nazi persecution has been passed on from generation to generation
Development of the memorial site and documentation center "denk.mal Hannoverscher Bahnhof"
Participation in the Research Training Group "Vergegenwärtigungen. Repräsentationen der Shoah in komparatistischer Perspektive" (Realizations: Representations of the Shoah in Comparative Perspective) of the University of Hamburg.
Project cooperation with the Universities of Hamburg and Augsburg to develop pedagogical materials on "Racisms in Colonialism and National Socialism"
"Military Justice and the City During the War" - Research Project on the Practice of Wehrmacht Courts in Hamburg During the Second World War.
"#Waswillstdutun? A multimedia project on the contemporary relevance of family history in the National Socialist era".
Passing On History from Generation to Generation: Building the Future of Remembrance of National Socialism in the Society Shaped by Migration
All special exhibitions designed by the Research and Exhibitions Department are available for loan and were initially presented at the Day of Remembrance for the Victims of National Socialism (International Holocaust Remembrance Day) in Hamburg City Hall. Examples:
Deported to Neuengamme Concentration Camp: Punitive Actions by the Wehrmacht and the SS in Occupied Europe (2015)
"Euthanasia": How the Nazis Murdered People with Disabilities and Mental Illness in Hamburg (2014)
Deserters and Other Victims of Persecution by the Nazi Military Judiciary: Wehrmacht Jurisdiction in Hamburg (2013)
Documenting the Stadthaus: The Hamburg Police under the Nazis (2012)
Neuengamme Concentration Camp and the Site after the War in Focus. Pictures of the Camp and Memorial (2011)
Other exhibitions: List of all exhibitions
The Foundation of Hamburg Memorials and Learning Centres is in charge of other third-party funded projects. Currently the project "Serious Game. The children of Bullenhuser Damm".
Head of Archive
Research and Exhibitions


Welcome Home to this 2 Bedroom 1 Bath home in the heart of Orrville, close to the park, restaurants and schools. This bungalow features a formal dining room as well as nice hardwood floors & woodwork. This home is ready for its new owner, Is that you? Call today to schedule your private showing.


text:
KXT Music Blog
Austin City Limits: The Pretenders
The Pretenders make their long-awaited Austin City Limits debut this week on KERA TV.
Courtesy of KLRU-TV/Austin City Limits. Photo by Scott Newton
It's been nearly four decades since The Pretenders' epochal 1980 debut album, and singer-songwriter/guitarist/goddess Chrissie Hynde is still shaking us to the core with that powerful, inimitable voice of hers. (In fact, we had the pleasure of seeing her in person in 2014 when she popped by for a KXT Live Session.) Led by and armed with original drummer Martin Chambers, The Pretenders come to Austin City Limits in support of latest album, Alone. Tune in for an unforgettable, career-spanning set.
Watch the full episode this Tuesday, October 17 at 10pm on KERA TV!
Tags: austin city limits, Chrissie Hynde, The Pretenders


Only numbers, no space and special characters.
All starred fields are mandatory to be filled. Contact e-mail address is the unique parameter and one e-mail cannot be used for more than one account. If you already have an account your e-mail address is linked to, and you wish to register another account (for a different legal entity or a different person) it is necessary to use a different e-mail address. All Customer information is kept strictly confidential and shall be made available only to those employees whom this information is necessary in order to perform their job duties and identify the customer in order to prevent possible fraud and abuse. All SBB employees must comply with privacy protection rules and regulations.


text:
FROM stackbrew/debian:sid
MAINTAINER Johan Euphrosine <proppy@google.com>

RUN echo 'deb-src http://http.debian.net/debian sid main' >> /etc/apt/sources.list
RUN apt-get update && apt-get install -yq git dh-golang golang build-essential devscripts equivs libcrypt-ssleay-perl lintian --no-install-recommends
ADD . /usr/src/golang-gocapability-dev/debian/
WORKDIR /usr/src/golang-gocapability-dev
RUN mk-build-deps -irt'apt-get --no-install-recommends -yq' debian/control

RUN (cd /tmp && bash -x /usr/src/golang-gocapability-dev/debian/README.Source && cp *.orig.tar.gz /usr/src)
RUN (cd /usr/src && tar xvzf /usr/src/*.orig.tar.gz)

CMD [ "debuild", "-us", "-uc" ]


Hotel Athgira features accommodation with an outdoor swimming pool. With a garden, the property also features a shared lounge. The accommodation offers a 24-hour front desk as well as free WiFi. At the hotel each room includes a balcony with pool view. Hotel Athgira provides some units that have garden views, and all rooms are equipped with a private bathroom with a shower. The rooms are fitted with a TV with satellite channels.A halal, Asian or continental breakfast can be enjoyed in the breakfast area.


In a large frying pan place 1 tblspoon of the olive oil and the garlic, saute over medium heat until the garlic is fragarant, about 30 sec ( dont let it brown). Add the kale, with any water clinging to it from washing. Season generously with salt and pepper and increase the heat to medium high. Cook, tossing frequently, until the kale is wilted and tender, about 12 to 20 mins depending on the variety (you can add more water if it starts to look dry).
Meanwhile, heat the oven to 400F. Toss the beets with another tablespoon of olive oil, season with salt and pepper and spread on a baking sheet. Roast until tender and starting to brown slightly, about 20 minutes.
While the beets are cooking, put the remaining 2 tblspoons of olive oil in a frying pan over medium high. Add onion and thyme, season with some sale and cook, stirring frequently, until the onions are soft, sweet, fragrant and carmelized, about 20 minutes.
Once the beets are out of the oven, increase heat to 475F. Line baking sheet with parchment or use baking stone. Roll out pizza dough on floured surface. Transfer to stone or pan covered in parchment. Distribute kale, onions, beets and cover with cheese.
Bake until crust is golden brown, the underside looks crisp and brown and the cheese is bubbling, 18 to 25 minutes. Cut into wedges and serve immediately.
Also, this recipe comes from Farmstand Fresh magazine, which was published by Fine Cooking. We highly recommend it- so many good recipes for CSA members!
Optional extra flavors such as garlic, hot peppers, herbs, etc.
Rustle up a gallon jar, or several smaller canning jars (or scale the recipe to what you have available).
Heat the water and vinegar until steamy, and add the salt and pickling spices. Simmer about 5 minutes.
Leave cucumbers whole or slice to fit the jars. Pour the hot vinegar mixture into the jars slowly, enough to cover the cucumbers. Fasten lids and let stand at room temperature until they cool.
Refrigerate. Taste test in about two weeks. We find the pickles are best if eaten within a few months, though the carrots will keep longer than the cucumbers.
You can also process the jars so they are shelf stable at room temperature, but this tends to make the pickles mushy. We prefer to forego the processing and keep the pickles in the fridge.
*For pickling spice, we buy the blend from Echo Hill Country Store in Fleetwood. You could just as well find a blend at the grocery store or make your own. Add additional flavorings to taste. We like just enough hot pepper or garlic to add some zing.